ArkGen BioScions
ARKGEN BioScions is a biotech pioneering the development of novel therapies for cancers. We currently focus on two core platforms:
1. Multi-specific antibody: AMB
- ARK102 (TROP2 x HER2 x CD3): in vivo results of ARK102 for NSCLC have shown complete response for all mice, confirming better efficacy than HER2 ADC and TROP2 ADC.
- Confirmed developability of Tetra-specific, Penta-specific antibodies.
2. Cancer vaccine: RP-TCV (First-in-class personalized recombinant protein neoantigen cancer vaccine)
- In vivo results for BF16-10 and CT-26 have shown better efficacy than BioNTech’s peptide cancer vaccine.
- Confirmed increased TIL
We are seeking companies for collaboration and licensing opportunities across our assets.
Keywords: NSCLC, TROP2, multi-specific antibody, tri-specific, tetra-specific, penta-specific, immuno-oncology, oncology, immunotherapy, recombinant protein, neoantigen, te, t cell engager, tumor, therapeutic cancer vaccine, personalized cancer vaccine
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}